- Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes
-
Li X, Li Z, Li L, Liu T, Qian C, Ren Y, Li Z, Chen K, Ji D, Zhang M, Wang J
- KMID: 2550330
- Cancer Res Treat.
- 2024 Jan;56(1):134-142.
- doi: 10.4143/crt.2023.652
Purpose Tamoxifen showed individual differences in efficacy under different CYP2D6*10 genotypes. Our study evaluated the prognosis of tamoxifen or toremifene in hormone receptor (HR)–positive breast cancer patients under different genotypes. Materials... -
- CITED
-
- Close
- SHARE
-
- Close
